Tasly Pharmaceutical Group Co., Ltd
600535
Classement en actions
#4771
Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in... Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.
Prix de l'action
$2.05
Capitalisation boursière
$3.07B
Changement (1 jour)
-1.37%
Changement (1 an)
-7.80%
Pays
CN
Échange Tasly Pharmaceutical Group Co., Ltd (600535)
Catégorie
Healthcare
Bénéfices pour Tasly Pharmaceutical Group Co., Ltd (600535)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Tasly Pharmaceutical Group Co., Ltd, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Tasly Pharmaceutical Group Co., Ltd de 2001 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2025 | $192.27M | 31.32% |
| 2024 | $146.41M | -15.13% |
| 2023 | $172.51M | -809.84% |
| 2022 | $-24.30M | -105.67% |
| 2021 | $428.51M | 92.12% |
| 2020 | $223.04M | 16.70% |
| 2019 | $191.12M | -32.79% |
| 2018 | $284.34M | 6.54% |
| 2017 | $266.90M | 23.84% |
| 2016 | $215.52M | -22.05% |
| 2015 | $276.48M | -1.18% |
| 2014 | $279.80M | 19.89% |
| 2013 | $233.39M | 34.76% |
| 2012 | $173.19M | 38.94% |
| 2011 | $124.65M | 48.07% |
| 2010 | $84.18M | 44.00% |
| 2009 | $58.46M | 26.80% |
| 2008 | $46.10M | 49.47% |
| 2007 | $30.84M | -8.16% |
| 2006 | $33.58M | 16.86% |
| 2005 | $28.74M | 10.44% |
| 2004 | $26.02M | 22.03% |
| 2003 | $21.32M | 21.82% |
| 2002 | $17.50M | 12.42% |
| 2001 | $15.57M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
